Closing the Gaps in NSCLC

With newly approved therapies on the rise, the way we treat non-small cell lung cancer patients with a RET gene rearrangement may be evolving. That’s why it’s so important to test for RET mutations in patients with non-small cell lung cancer, as oncologist Dr. Deepa Rangachari explains.

Survival rates for patients with non-small cell lung cancer have notably improved thanks to the development of targeted therapies and immunotherapies. With these recent advancements on the forefront, Dr. Deepa Rangachari joins Dr. Jennifer Caudle to discuss the KEYNOTE-189 study and how it could change our approach to treating patients with non-small cell lung cancer.

Living with non-small cell lung cancer means living with a daily burden of symptoms like fatigue, decreased appetite, and shortness of breath. Dr. Deepa Rangachari, an oncologist at Harvard’s Beth Israel Deaconess Medical Center, expresses the importance of finding therapeutic strategies to help patients manage symptoms.

The COVID-19 pandemic has presented a unique and difficult problem for clinicians and patients alike. Here to share how he’s continuing treatment for his patients with non-small cell lung cancer in the era of COVID-19 is Dr. Joshua Bauml, a medical oncologist and Assistant Professor at the Perelman School of Medicine at the University of Pennsylvania.

Targeted therapies for oncogenic mutations in non-small cell lung cancer have shown a lot of potential when it comes to tailoring systemic treatment strategies to more specific tumor types and mutations. But just like any other therapeutic approach, it’s not without its challenges.

To learn more about how we can identify these oncogenic drivers in our patients and what we should keep in mind when using targeted therapies, Mario Nacinovich sits down Dr. Lyudmila Bazhenova, board-certified medical oncologist and Professor of Medicine at the University of California San Diego.

When a patient with non-small cell lung cancer harboring a molecular driver alteration develops resistance to their therapy, it’s important that we identify what the source of that resistance is, as Dr. Joshua Bauml from the University of Pennsylvania explains.

Now that there are more targeted therapies available for metastatic non-small cell lung cancer, what are the best practices for evaluating our patients? Dr. Joshua Bauml elaborates on the opportunities and challenges faced when testing for oncogenic drivers in non-small cell lung cancer.

When a patient presents with non-small cell lung cancer, one question that comes up is: Could this patient have a RET fusion? Here to explore how we can answer that question is Dr. Joshua Bauml, medical oncologist and Assistant Professor at the University of Pennsylvania’s Perelman School of Medicine.

Tune in to hear medical oncologist Dr. Joshua Bauml from the University of Pennsylvania explain the difference between RET fusions and RET point mutations and how they each affect our treatment approach.

Here to walk us through our current understanding of oncogene addiction and the resulting progress that’s been made in lung cancer treatment is Dr. Fred Hirsch from Mount Sinai.